Patients with certain advanced hereditary breast cancers may have new treatments options on the horizon, according to two studies presented at the annual San Antonio Breast Cancer Symposium. Susan Domchek, MD, executive director of the Basser Center for BRCA at Penn’s Abramson Cancer Center, presents new results from the Mediola and OlympiAD trials showing continued success of treating BRCA-related metastatic breast cancer with the PARP inhibitor olaparib with limited side effects for patients.
Experts from the Perelman School of Medicine at the University of Pennsylvania will be presenting data on the latest advances in cancer research and treatment at the 59th ASH Annual Meeting and Exposition in Atlanta from December 8-12.
Female Parkinson’s disease patients are much less likely than male patients to have caregivers, despite the fact that caregivers report greater strain in caring for male patients. The findings come from a large study reported today in Neurology by researchers at the Perelman School of Medicine at the University of Pennsylvania.
For Patients and the General Public: